Brief: Celldex Therapeutics Announces Positive Results From Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria

Celldex Therapeutics

06/11/2023 11:37

Nov 6 (Reuters) - Celldex Therapeutics Inc  CLDX.O :
    * CELLDEX THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS
FROM
BARZOLVOLIMAB PHASE 2 STUDY IN CHRONIC SPONTANEOUS URTICARIA
    * CELLDEX THERAPEUTICS INC: BARZOLVOLIMAB MET PRIMARY
ENDPOINT
    * CELLDEX THERAPEUTICS INC: BARZOLVOLIMAB WAS GENERALLY WELL
TOLERATED WITH A FAVORABLE SAFETY PROFILE
    * CELLDEX THERAPEUTICS INC: MEAN CHANGE FROM BASELINE TO
WEEK 12
IN UAS7 OF -23.87 IN 300 MG Q8W DOSE GROUP AND -23.02 IN 150 MG
Q4W DOSE GROUP
    * CELLDEX THERAPEUTICS INC: TREATMENT WILL CONTINUE TO 52
WEEKS;
RESULTS SUPPORT FURTHER DEVELOPMENT OF BARZOLVOLIMAB IN PHASE 3
CSU STUDIES
    * CELLDEX THERAPEUTICS INC: DATA FROM 208 PATIENTS
RANDOMIZED IN
STUDY SHOWED THAT BARZOLVOLIMAB ACHIEVED PRIMARY EFFICACY
ENDPOINT
    * CELLDEX THERAPEUTICS: CLINICALLY MEANINGFUL &
STATISTICALLY
SIGNIFICANT DECREASES IN URTICARIA DISEASE ACTIVITY ACROSS
MULTIPLE DOSE GROUPS IN STUDY

Source text for Eikon:  ID:nGNX19qQYq 
Further company coverage:  CLDX.O 

 ((Reuters.Briefs@thomsonreuters.com;))